AUG 17, 2026 · JOURNAL ARTICLE
Enzalutamide‐Induced Host Metabolic Reprogramming Is Associated with Treatment Outcomes in Patients with Castration‐Resistant Prostate Cancer: A Hypothesis‐Generating Study
Clinical Pharmacology & Therapeutics
A small, single-centre, uncontrolled exploratory study with mechanistic in vitro validation that raises the question of whether metabolomic signatures predict enzalutamide response, but does not yet answer it with prospective validation or clinical outcomes.
Reported
Sample size18
Enzalutamide dose160 mg/day
Timepoint of metabolomic samplingbaseline, 3 months, and until disease progr…